TY - JOUR
T1 - Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells
AU - Morello, V.
AU - Cabodi, S.
AU - Sigismund, S.
AU - Camacho-Leal, M. P.
AU - Repetto, D.
AU - Volante, M.
AU - Papotti, M.
AU - Turco, E.
AU - Defilippi, P.
PY - 2011/9/29
Y1 - 2011/9/29
N2 - Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.
AB - Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.
KW - β1 integrin
KW - EGFR
KW - lung cancer
UR - http://www.scopus.com/inward/record.url?scp=80053320001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053320001&partnerID=8YFLogxK
U2 - 10.1038/onc.2011.107
DO - 10.1038/onc.2011.107
M3 - Article
C2 - 21478906
AN - SCOPUS:80053320001
VL - 30
SP - 4087
EP - 4096
JO - Oncogene
JF - Oncogene
SN - 0950-9232
IS - 39
ER -